SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.400.0%Nov 28 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pierre Borczuk who wrote (918)6/6/2001 10:58:22 AM
From: keokalani'nui   of 1475
 
>>Data from MedImmune's Phase I program with MEDI-507 will be reviewed in an oral presentation at 12:30 p.m. on June 23, 2001 in San Francisco at the International Psoriasis Symposium and European Congress on Psoriasis. The MEDI-507 studies that will be included in the presentation include a Phase I, open-label, single-dose intravenous safety study; a Phase I/II, open-label, dose-escalation study involving 8-weekly intravenous infusions; and a Phase I/II, open-label, dose-escalation study involving 12-weekly subcutaneous injections. Reductions in PASI scores have been observed in these studies.<<

biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News